Vera Therapeutics, Inc.

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives. Their mission is to change the standard of care for patients with immunologic and rare diseases. Their lead late-stage clinical candidate, atacicept, is a fully humanized TACI-Fc fusion protein that inhibits the two cytokines, BAFF and APRIL, that cause B cells and plasma cells to produce disease-causing antibodies. Atacicept is a potential best- and first-in-class dual BAFF/APRIL B cell modulator for IgA Nephropathy (IgAN), a B cell-mediated kidney disease that often progresses to kidney failure despite optimized supportive care.

In addition to atacicept, Vera Therapeutics holds worldwide global rights to MAU868, a monoclonal antibody that neutralizes infection by blocking BK virus (BKV) binding to host cells. MAU868 is the first neutralizing antibody targeting the BK Virus (BKV). BKV is a polyoma virus that can be reactivated when a patient is immunocompromised, such as in kidney transplant and hematopoietic stem cell transplant (HSCT) recipients.

Vera Therapeutics offers a flexible hybrid work environment, minimizing the collective commute time and environmental impact. This allows employees to work both in the office and remotely, providing them with a better work-life balance and allowing them to work from where they are most productive.

Vera Therapeutics offers a comprehensive benefits package to its employees, including medical, dental, and vision insurance with flexible spending accounts, life and disability insurance, flexible time off, company-paid holidays, an employee stock purchase plan, a 401(k) retirement savings plan with a match program, an employee assistance program, and a mobile phone stipend. Additionally, employees enjoy catered weekly lunches, an on-site gym, team-building events, opportunities for volunteer work, recognition of work anniversaries, and a convenient location near San Francisco.

Vera Therapeutics is a clinical-stage biotechnology company committed to developing novel treatments for patients with immunological and rare diseases. Their mission is to change the standard of care for these patients by targeting the source of their diseases, ultimately improving their quality of life and longevity.

Vera Therapeutics fosters a collaborative and inclusive culture that values empathy, accountability, and clear communication. They encourage a sense of ownership among employees, fostering an environment where individuals feel respected, valued, and engaged. The company invests in its employees through a comprehensive learning curriculum and recognizes achievements through various awards. Vera Therapeutics also prioritizes giving back to the community, promoting volunteerism and supporting a sustainable and equitable future.

Vera Therapeutics embraces diversity, equity, and inclusion as core values, believing that innovation thrives in a workforce enriched by diverse backgrounds and perspectives. They strive to not only hire diverse talent but also foster an environment where all employees feel respected, valued, and engaged. They demonstrate this commitment through initiatives like the Vera Culture Club, which focuses on creating a respectful and vibrant work environment, as well as by continually assessing and adapting their DEI efforts to ensure all members of Team Vera feel a sense of belonging.